Topical treatments for scalp psoriasis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Schlager, Justin Gabriel ^a   Rosumeck, Stefanie ^a   Werner, Ricardo Niklas ^a   Jacobs, Anja ^b   Schmitt, Jochen ^c   Schlager, Christoph ^d   Nast, Alexander ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Medical Consulting ^*  (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMCINONIDE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CICLOPIROXOLAMINE; CLOBETASOL PROPIONATE; COAL TAR; COCOIS; COCONUT OIL; DESOXIMETASONE; DITHRANOL; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; HYDROCORTISONE BUTYRATE; MOMETASONE FUROATE; PINE TAR; PSORADEXAN; SALICYLIC ACID; TACROLIMUS; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UREA; VITAMIN D; DERMATOLOGICAL AGENT; STEROID;

ABSENCE OF SIDE EFFECTS; ACNE; ALOPECIA; BURNING SENSATION; CEREBROVASCULAR ACCIDENT; CROSSOVER PROCEDURE; DEPRESSION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; EMULSION; ERYTHEMA; FOAM; FOLLICULITIS; HUMAN; HYDROPHILICITY; LONG TERM CARE; LOTION; META ANALYSIS; META ANALYSIS (TOPIC); MONOTHERAPY; NAUSEA; NUMBERS NEEDED TO TREAT; PAIN; PARALLEL DESIGN; PRURITUS; PUBLISHING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCALP PSORIASIS; SHORT COURSE THERAPY; SINGLE BLIND PROCEDURE; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN PAIN; SKIN TIGHTNESS; SYSTEMATIC REVIEW; TOPICAL TREATMENT; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; URTICARIA; CHRONIC DISEASE; PSORIASIS; SCALP DERMATOSES; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; CHRONIC DISEASE; DERMATOLOGIC AGENTS; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCALP DERMATOSES; STEROIDS; VITAMIN D;

EID: 84961966643     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009687.pub2     Document Type: Review

References (208)

1. Andres P, Poncet M, Farzaneh S, Soto P. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. Journal of Drugs in Dermatology 2006;5(4):328-32. [MEDLINE: 16673799]
2. Barrett C, Lowson D, Blades KJ. Limited benefit of combined use of tar-based shampoo with 50 mug/ml calcipotriol solution in scalp psoriasis. Journal of Dermatological Treatment 2005;16(3):175. [EMBASE: 2005434030]
3. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003;72(5):407-11. [MEDLINE: 14655784]
4. Breneman DL, Davis MB, Berger V, Chaney R. A double-blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. Journal of Dermatological Treatment 1992;3(1):19-21. [EMBASE: 1992153744]
5. Buckley C, Hoffmann V. Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). (Abstract P06.57). Journal of the European Academy of Dermatology & Venereology 2005;19(Suppl 2):175.
6. Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008;217(2):107-13. [MEDLINE: 18463448]
7. Curley RK, Vickers CF, Norris T, Glover DR. A comparative study of betamethasone dipropionate with salicylic acid and betamethasone valerate for the treatment of steroid-responsive dermatoses of the scalp. Journal of Dermatological Treatment 1990;1(4):203-6. [EMBASE: 1990343409]
8. De Cuyper C, De Greef H, De La Brassinne M, Delescule J, Derumeuax L, Heenen M, et al. A randomized single-blind study to compare hydrocortisone 17-butyrate 0.1% emulsion versus betamethasone 17, 21-dipropionate 0.05% lotion in the treatment of patients suffering from psoriasis of the scalp. Journal of the European Academy of Dermatology & Venereology 1995;5(Suppl 1):S104-5.
9. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, Abdulla SA. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. International Journal of Clinical Pharmacology Research 2000;20(3-4):65-8. [MEDLINE: 11314240]
10. Ellis CN, Horwitz SN, Menter A. Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Current Therapeutic Research - Clinical and Experimental 1988;44(2):315-24. [EMBASE: 1989002095]
11. Ellis CN, Menter MA. A randomized, blinded comparison of amcinonide lotion and fluocinonide solution in patients with psoriasis of the scalp. Current Therapeutic Research - Clinical and Experimental 1989;46(3):471-7. [EMBASE: 1989232557]
12. Feldman SR, Ravis SM, Fleischer AB, McMichael A, Jones E, Kaplan R, et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. Journal of Cutaneous Medicine & Surgery 2001;5(5):386-9. [MEDLINE: 11907847]
13. Feldman SR, Mills M, Brundage T, Eastman WJ. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. Journal of Drugs in Dermatology 2013;12(3):300-6. [MEDLINE: 23545912]
14. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology 1999;38(8):628-32. [MEDLINE: 10487457]
15. Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology 2000;39(7):535-8. [MEDLINE: 10940121]
16. Fredriksson T. A clinical comparison of 3 corticosteroid alcoholic solutions in the treatment of psoriasis of the scalp. Pharmatherapeutica 1976;1(4):252-6. [EMBASE: 0977155168]
17. Gip L. Hydrocortisone 17-butyrate 0.1% cream and fluocinolone acetonide 0.025% cream: a double-blind comparison in patients suffering from psoriasis of the scalp. Current Therapeutic Research - Clinical and Experimental 1981;29(1 II):198-201. [EMBASE: 1981110060]
18. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. British Journal of Dermatology 1994;130(4):483-7. [MEDLINE: 8186114]
19. Griffiths C, Barker J, Finlay A, Mizzi F, Arsonnaud S. A new formulation of clobetasol proprionate is more effective and safer than 1% tar shampoo in scalp. Annales de Dermatologie et de Vénéréologie 2002;129:1S740.
20. Griffiths C, Barker J, Finlay A, Mizzi F, Arsonnaud S. A new formulation of clobetasol proprionate is safe and more effective than 1% tar shampoo in scalp psoriasis. Journal of the European Academy of Dermatology & Venereology 2002;16(Suppl 1):277.
21. Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. Journal of Dermatological Treatment 2006;17(2):90-5. [MEDLINE: 16766333]
22. Harris JJ. A national double-blind clinical trial of a new corticosteroid lotion: a 12-investigator cooperative analysis. Current Therapeutic Research, Clinical & Experimental 1972;14(9):638-46. [MEDLINE: 4263888]
23. He YL, Guo ZP. Clinical efficacy of 0.1% tacrolimus ointment on plaque psoriasis of scalp and face. Journal of Clinical Dermatology 2008;37(4):254-5. [EMBASE: 2008250949]
24. Hillstrom L, Pettersson L. Studies with betamethasone dipropionate lotion with salicylic acid (Diprosalic) in psoriasis and seborrhoic eczema of the scalp. Current Therapeutic Research - Clinical and Experimental 1978;24(1):46-50. [EMBASE: 0979244015]
25. Hillstrom L, Pettersson L, Svensson L. Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic(TM)) and clobetasol propionate lotion (Dermovate(TM)) in the treatment of psoriasis of the scalp. Journal of International Medical Research 1982;10(6):419-22. [MEDLINE: 7152080]
26. Hillstrom L. Comparison of topical treatment with desoxymethasone solution 0.25% with salicylic acid 1% and betamethasone valerate solution 0.1% in patients with psoriasis of the scalp. Journal of International Medical Research 1984;12(3):170-3. [MEDLINE: 6734919]
27. Housman TS, McMichael AJ, Mellen BG, Derrow AE, McCarty MA, Feldman SR. Use of 0.12% betamethasone valerate foam vs 0.01% fluocinolone acetonide topical oil to treat scalp psoriasis: quantitative assessment of patient preference and treatment efficacy. Cosmetic Dermatology 2002;15(11):27-30. [EMBASE: 2006007462]
28. Housman TS, McMichael AJ, Mellen BG, Derrow E, McCarty MA, Feldman SR. Betamethasone valerate foam vs. fluocinolone acetonide topical oil in the treatment of scalp psoriasis: quantitative assessment of patients' preference and efficacy (Abstract 203). Journal of Investigative Dermatology 2002;119(1):241.
29. Jarratt M, Davis JG, Giltner MP, Jones ML, Peets EA. Comparative studies of augmented betamethasone dipropionate lotion 0.05% and clobetasol propionate solution 0.05%: Correlation of the vasoconstriction assay and clinical activity in scalp psoriasis. Advances in Therapy 1991;8(2):103-11. [EMBASE: 1991176103]
30. Claudel J-P, Fredon L, Maccari F, Savary J. Nantes, March 26, 2009: A new response to psoriasis of the scalp: Clobex®, first corticosteroid shampoo [Nantes, le 26 mars 2009: Une nouvelle réponse au psoriasis du cuir chevelu: Clobex®, premier shampooing corticoïde]. Nouvelles Dermatologiques 2009;28(6 Pt 1):341-4. [EMBASE: 2009457722]
31. Jarrat M, Beneman D, Gottlieb A, Poulin Y, Foley V. Efficacy and safety comparison of clobetasol proprionate shampoo 0.05% and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology & Venereology 2002;16(Suppl 1):282-3.
32. Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology 2004;3(4):367-73. [MEDLINE: 15303780]
33. Jemec GB, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno P, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Journal of the American Academy of Dermatology 2008;59(3):455-63. [MEDLINE: 18694678]
34. Jemec GBE, Burden D, Poulin Y, Ortonne JP. A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients and the vehicle (Abstract P2733). Journal of the American Academy of Dermatology 2007;56(2):AB182.
35. Josse M, Mengeaud V, Khemis A. Efficacy of a new keratolytic shampoo containing glycolic acid and ictyol for the treatment of scalp psoriasis: results of a comparative study (Abstract P1604). Journal of the American Academy of Dermatology 2006;54(3 Suppl):AB128.
36. Josse M, Mengeaud V, Khemis A, Ortonne JP. Efficacy of a new keratolytic shampoo containing glycolic acid and ictyol for the treatment of scalp psoriasis - results of a comparative study (Abstract P16.34). Journal of the European Academy of Dermatology & Venereology 2005;19(Suppl 2):391.
37. Katz HI, Lindholm JS, Weiss JS, Shavin JS, Morman M, Bressinck R, et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clinical Therapeutics 1995;17(3):390-401. [MEDLINE: 7585843]
38. Kiss I, McCreary HL, Siskin SB, Epinette WW. A randomized, double - blind, parallel group dose ranging comparison of the efficacy and safety of calcipotriene solution in the treatment of scalp psoriasis. American Academy of Dermatology. 54th annual meeting February 10-15. Journal of the American Academy of Dermatology 1996:P301.
39. Kiss I, McCreary HL, Siskin SB, Epinette WW. A randomized, double - blind, parallel group dose ranging comparison of the efficacy and safety of calcipotriene solution in the treatment of scalp psoriasis. American Academy of Dermatology. 54th annual meeting February 10-15. Journal of the American Academy of Dermatology 1996:P301.
40. Klaber MR, Hutchinson PE, Pedvis-Leftick A, Kragballe K, Reunala TL, van de Kerkhof PC, et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology 1994;131(5):678-83. [MEDLINE: 7999600]
41. Klaber MR, McKinnon C. Calcipotriol (Dovonex©) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (Capasal©) shampoo, and long-term experience. Journal of Dermatological Treatment 2000;11(1):21-8. [EMBASE: 2000114933]
42. Köse O. Calcipotriol ointment vs clobetasol solution in scalp psoriasis. Journal of Dermatological Treatment 1997;8(4):287. [EMBASE: 1998022654]
43. Kragballe K, Ganslandt C, Ortonne JP. A calcipotriol plus betamethasone dipropionate scalp formulation significantly reduces itching in scalp psoriasis. Abstract P3343. American Academy of Dermatology 67th Annual Meeting March 6-10, 2009. Journal of the American Academy of Dermatology 2009;60(3 Suppl 1):AB172.
44. Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology 2009;161(1):159-66. [MEDLINE: 19416259]
45. NCT00243464 . A calcipotriol plus betamethasone diproprionate scalp formulation significantly reduces itching in scalp. www.clinicaltrials.gov/show/NCT00243464?term=NCT00243464 (accessed 5 November 2014).
46. Ortonne JP, Ganslandt C, Tan J, Nordin P, Kragballe K, Segaert S. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. Journal of the European Academy of Dermatology & Venereology 2009;23(8):919-26. [MEDLINE: 19453810]
47. Lassus A. Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone-17, 21-dipropionate: a double-blind comparison. Current Medical Research & Opinion 1976;4(5):365-7. [MEDLINE: 795609]
48. Lepaw MI. Double-blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis 1978;21(4):571-3. [MEDLINE: 346315]
49. Cambazard F. Xamiol, a new treatment in scalp psoriasis: short- and long-term results [Un nouveau traitement dans le psoriasis du cuir chevelu : Xamiol®: Résultats à court terme et à long terme]. Annales de Dermatologie et de Vénéréologie 2009;136(Suppl 3):546-50. [EMBASE: 2009406816]
50. Luger TA, Cambazard F, Larsen FG, Bourcier M, Gupta G, Clonier F, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008;217(4):321-8. [MEDLINE: 18787325]
51. Medansky RS, Handler RM. Treating psoriasis of the scalp with a new corticosteroid lotion. Illinois Medical Journal 1974;145(6):503-4. [MEDLINE: 4152499]
52. Monk BE, Mason RBS, Munro CS, Darley CR. An open and single-blind comparative assessment of unguentum cocois compound in the treatment of psoriasis of the scalp. Journal of Dermatological Treatment 1995;6(3):159-61. [EMBASE: 1995319726]
53. NCT01195831 . Efficacy and safety of Xamiol® gel compared to calcipotriol scalp solution in patients with scalp psoriasis. clinicaltrials.gov/show/NCT01195831 (accessed 5 November 2014).
54. Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology 1991;24(3):443-7. [MEDLINE: 2061442]
55. Pauporte M, Maibach H, Lowe N, Pugliese M, Friedman DJ, Mendelsohn H, et al. Fluocinolone acetonide topical oil for scalp psoriasis. Journal of Dermatological Treatment 2004;15(6):360-4. [MEDLINE: 15764047]
56. Regana MS, Mirada A, Trullás C, Dilmé E. Increased efficacy and acceptability of a nonecoal tar shampoo for scalp psoriasis: Better efficacy and acceptability. 67th Annual Meeting of the American Academy of Dermatology, AAD San Francisco, CA United States. Conference Start: 20090306 Conference End: 20090310. Journal of the American Academy of Dermatology 2009;60(3 Suppl 1):AB179. [EMBASE: 70142428]
57. Reygagne P, Diaconu J, Près H, Ernst TM, Meyer KG. Efficacy and safety comparison of clobetasol proprionate shampoo, gel and vehicle in scalp psoriasis. Journal of the European Academy of Dermatology & Venereology 2002;16(Suppl 1):283.
58. Reygagne P, Mrowietz U, Decroix J, de Waard-van der Spek FB, Acebes LO, Figueiredo A, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment 2005;16(1):31-6. [MEDLINE: 15897165]
59. Reygagne P, Mrowietz U, Decroix J, van der Spek W, Olmos Acebes L, et al. Four-week efficacy and safety comparison of a new clobetasol shampoo and calcipotriol solution 0.005% in subjects with scalp psoriasis. Journal of the European Academy of Dermatology & Venereology 2002;16(Suppl 1):285.
60. Ruzicka T, Trompke C. Treatment of scalp psoriasis. An effective and safe tacalcitol emulsion [Behandlung der Kopfhaut-Psoriasis: Gute Wirksamkeit und Sicherheit durch Tacalcitol-Emulsion]. Hautarzt 2004;55(2):165-70. [MEDLINE: 14968327]
61. Shuttleworth D, Galloway DB, Boorman GC, Donald AE. A double-blind, placebo-controlled study of the clinical efficacy of ciclopirox olamine (1.5%) shampoo for the control of scalp psoriasis. Journal of Dermatological Treatment 1998;9(3):163-7. [EMBASE: 1998346163]
62. Cook-Bolden FE, Goffe BS, Hudson CP, Sofen HL. Efficacy and safety results from a randomized, double-blind, vehicle-controlled study of clobetasol propionate spray for the treatment of moderate to severe plaque psoriasis of the scalp (Poster P3368) 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Journal of the American Academy of Dermatology 2010;62(3 Suppl 1):AB140. [EMBASE: 70142994]
63. Cook-Bolden FE, Goffe BS, Hudson CP, Sofen HL. Patient satisfaction with clobetasol propionate spray, 0.05% for the management of moderate to severe plaque psoriasis of the scalp. 70th Annual Meeting of the American Academy of Dermatology San Diego, CA United States. Conference Start: 20120316 Conference End: 20120320. Journal of the American Academy of Dermatology 2012;66(4 Suppl 1):AB197. [EMBASE: 70704639]
64. Cook-Bolden FE, Goffe BS, Sofen HL, Colon LE, Gottschalk RW. Successful treatment of moderate to severe plaque psoriasis of the scalp with clobetasol propionate spray, 0.05% (Abstract P3347). 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA United States. Conference Start: 20110204 Conference End: 20110208. Journal of the American Academy of Dermatology 2011;64(2 Suppl 1):AB157. [EMBASE: 70331905]
65. Cook-Bolden FE, Goffe BS, Sofen HL, Hudson CP, Colon LE, Gottschalk RW, et al. Patient satisfaction with clobetasol proprionate spray, 0.05% for the treatment of moderate to severe plaque psoriasis of the scalp. 36th Annual Hawaii Dermatology Seminar of the Skin Disease Education Foundation Waikoloa, HI United States. Conference Start: 20120219 Conference End: 20120224. Seminars in Cutaneous Medicine & Surgery 2012;31(1):A9-A10. [EMBASE: 70706927]
66. Sofen H, Hudson CP, Cook-Bolden FE, Preston N, Colon LE, Caveney SW, et al. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. Journal of Drugs in Dermatology 2011;10(8):885-92. [MEDLINE: 21818510]
67. Swinehart JM, Barkoff JR, Dvorkin D, Fisher G, Peets E. Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis. International Journal of Dermatology 1989;28(10):680-1. [MEDLINE: 2687182]
68. Tyring S, Mendoza N, Appell M, Bibby A, Foster R, Hamilton T, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. International Journal of Dermatology 2010;49(11):1328-33. [MEDLINE: 20964660]
69. Van de Kerkhof PC, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, et al. Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 2002;204(3):214-21. [MEDLINE: 12037450]
70. van de Kerkhof P, Anstey A, Barnes L, Bolduc C. A new scalp formulation of calcipotriene plus betamethasone in the treatment of scalp psoriasis compared to its active ingredients in the same vehicle. Journal of the American Academy of Dermatology 2007;56(2):AB182.
71. van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. British Journal of Dermatology 2009;160(1):170-6. [MEDLINE: 19067709]
72. Van der Ploeg DE, Cornell RC, Binder R, Weintraub JS, Jarratt M, Jones ML, et al. Clinical trial in scalp psoriasis mometasone furoate lotion 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Therapeutica 1989;15(2):145-52.
73. Wall ARJ, Bibby AJ. Combined use of calcipotriol solution (50 ug/ml) and Polytar Liquid in scalp psoriasis (Abstract P-689). Journal of the European Academy of Dermatology & Venereology 1999;12(Suppl 2):S337.
74. Wilhem KP, Ocker G, Tebbs V, Guilabert A. A new mometasone formulation (LAS 41002 emulsion with 36% water content) is effective, well tolerated and cosmetically acceptable in the treatment of scalp psoriasis. Abstract - 22nd Congress of the European Academy of Dermatology and Venereology, 2-6 October 2013, Istanbul. Journal of the European Academy of Dermatology & Venereology. 2013.
75. Willis I, Cornell RC, Penneys NS, Zaias N. Multicenter study comparing 0.05% gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Clinical Therapeutics 1986;8(3):275-82. [MEDLINE: 3521856]
76. Wright S, Mann RJ. Comparison of a cream containing 0.1% dithranol in a 17% urea base (Psoradrate(TM)) with coal tar pomade in the treatment of scalp psoriasis. Clinical & Experimental Dermatology 1985;10(4):375-8. [MEDLINE: 3899424]
77. Yilmaz H, Aydin F, Senturk N, Canturk T, Turanli AY. A comparison between the effects of calcipotriol lotion, momethasone furoate lotion and their combinations for the treatment of scalp psoriasis [Kalsipotriol Losyon, Mometazon Furoat Losyonve Kombinasyonlarinin Saçli Deri Psoriazisi Tedavisindeki Etkinliginin Karsilastirilmasi]. Turkderm Deri Hastaliklari ve Frengi Arsivi 2005;39(2):109-14. [EMBASE: 2006204571]
78. Andreassi L, Giannetti A, Milani M, Scale Investigators Group. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. British Journal of Dermatology 2003;148(1):134-8. [MEDLINE: 12534607]
79. Milani M. Efficacy of bettamousse on scalp psoriasis: the scale trial. Annales de Dermatologie et de Vénéréologie 2002;129:P2007.
80. Bohnsack K, Upmeyer H, Albrecht H, Treder-Conrad C, Scholermann A, Rippke F, et al. In-vivo assessment of the efficacy of an innovative anti-dandruff shampoo in subjects with scalp dermatitis (Abstract P02.1). 2004 Forum for Nordic Dermato-Venereology;9(Suppl 7):43.
81. Cassano N, Vena GA. Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product. Acta Dermato-Venereologica 2007;87(1):85-6. [MEDLINE: 17225026]
82. Cunliffe WJ, Dodman B. A comparison of tar liquid and cetrimide shampoo in the management of psoriasis of the scalp. British Journal of Clinical Practice 1974;28(9):314-5. [MEDLINE: 4464976]
83. Elie R, Durocher LP, Kavalec EC. Effect of salicylic acid on the activity of betamethasone-17, 21-dipropionate in the treatment of erythematous squamous dermatoses. Journal of International Medical Research 1983;11(2):108-12. [MEDLINE: 6852357]
84. Fallica L, De Prima T, Gasparri O, Panebianco R, Benedetti M. Clobetasone 17-butyrate, lotion scalp fluid. Results of a clinical trial in the treatment of steroid-sensitive dermatitis. Clinical Trials Journal 1989;26(6):393-400. [EMBASE: 1990069772]
85. Feng JC, Wang JB, Yu BT, Sun QN. Coal tar lotion in the treatment of 31 cases of scalp psoriasis. Chinese Journal of Dermatology 1997;30(2):84.
86. Heydendael VMR, de Borgie CAJM, Spuls PI, Bossuyt PMM, Bos JD, de Rie MA. The burden of psoriasis is not determined by disease severity only. Journal of Investigative Dermatology Symposium Proceedings 2004;9(2):131-5. [EMBASE: 2004161603]
87. Jakubowicz K, Ochman U. Psoriazin ointment in the treatment of psoriasis of the scalp (preliminary results) [Zastosowane masci psoriazin w leczeniu luszczycy skory owlosionej glowy (wyniki wstepne)]. Przeglad Dermatologiczny 1981;68(1):95-9. [MEDLINE: 7017821]
88. Kar PK, Rama Sastry CV. A study of combination therapy with puvasol and topical corticosteroid in psoriasis vulgaris involving scalp. Indian Journal of Dermatology 2000;43(3):130-5.
89. Kose O. 5 and 10 days occlusive treatment with calcipotriol in scalp psoriasis. Journal of the European Academy of Dermatology & Venereology 1995;3(Suppl 1):S148.
90. Kostarelos K, Teknetzis A, Lefaki I, Ioannides D, Minas A. Double-blind clinical study reveals synergistic action between alpha-hydroxy acid and betamethasone lotions towards topical treatment of scalp psoriasis. Journal of the European Academy of Dermatology & Venereology 2000;14(1):5-9. [EMBASE: 2001338533]
91. Lassus A, Lauharanta J, Kanerva L, Juvakoski T. Treatment of scalp psoriasis. A new dexamethasone preparation in a double-blind trial with hydrocortisone-17-butyrate [Behandlung der Kopfhautpsoriasis: Ein neues Dexamethason-Präparat im Doppelblindversuch mit Hydrocortison-17-butyrat]. Schweizerische Rundschau für Medizin/Praxis 1985;74(15):382-3. [EMBASE: 1985111490]
92. Lassus A, Forsstrom S. A double-blind study comparing oleum horwathiensis with placebo in the treatment of psoriasis. Journal of International Medical Research 1991;19(2):137-46. [EMBASE: 1991173914]
93. Lecewicz-Torun B, Chodorowska G. Clinical evaluation of hair shampoo 'Zdroj' for therapeutic use [Ocena kliniczna szamponu leczniczego do mycia wlosow 'Zdroj']. Przeglad Dermatologiczny 2001;88(2):177-80. [EMBASE: 2001227779]
94. Liu JH, Sun JF, Zeng XS, Zhang Q, Lin ML. Clinical observation on the efficacy of halometasone/triclosan (Sicorten Plus) cream in the treatment of scalp psoriasis. Chinese Journal of Dermatology 1994;27(5):325.
95. Nolting S, Hagemeier HH. Betamethasone-17, 21-dipropionate plus salicylic acid compared with betamethasone-dipropionate solution in the therapy of erythemato-squamous dermatoses [Therapie erythrosquamöser Dermatosen. Betamethason-Diproprionat plus Salizylsäure im Vergleich zu Betamethason-Diproprionat-Losung]. Fortschritte der Medizin 1983;101(37):1679-83. [EMBASE: 1983237084]
96. Rex Jr IH. A controlled evaluation of a new topical corticosteroid in psoriasis. Current Therapeutic Research - Clinical and Experimental 1973;15(11):833-8. [EMBASE: 0974140513]
97. Ross SD, Schachter RK. A randomized comparison of three conventional modes of treatment of psoriasis of the scalp. Cutis 1981;28(4):438-9. [EMBASE: 1982071447]
98. Saraceno R, Camplone G, D'Agostino M, De Simone C, Di Cesare A, Filosa G, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol gel) in the treatment of scalp psoriasis: results from a study in 885 patients. Journal of Dermatological Treatment 2014;25(1):30-3. [EMBASE: 2013799031]
99. Singh S, Byadgi PS, Rai NP. Clinical evaluation of Virechan therapy and Haridradi Vati and oil for the management of Kitibh Kushtha (psoriasis). International Journal of Research in Ayurveda and Pharmacy 2013;4(2):207-11. [EMBASE: 2013400892]
100. Taneja A, Racette A, Gourgouliatos Z, Taylor CR. Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study. International Journal of Dermatology 2004;43(6):462-7. [EMBASE: 2004286060]
101. Texier L, Gauthier O. Clinical trial of a lotion containing betamethasone dipropionate in the treatment of scalp dermatoses [Experimentation clinique d'une lotion au dipropionate de betamethasone (diprosone) dans le traitement des dermatoses du cuir chevelu]. Bordeaux Medical 1978;11(3):231-5. [EMBASE: 0978268779]
102. Tsankov N. Treatment of scalp psoriasis with 2% ketoconazole shampoo and Psanol®. Journal of the European Academy of Dermatology & Venereology 1995;5(Suppl 1):S104.
103. Tsankov N. Treatment of scalp psoriasis with Psanol and 2% ketaconazol shampoo: a double-blind, placebo-controlled study. Journal of the European Academy of Dermatology & Venereology 1998;11(Suppl 2):S287.
104. Williams DI, Warner J, Wilson LC. Betamethasone 17-valerate: a new alcoholic formulation for psoriasis of the scalp. British Medical Journal 1967;1(5536):344-5. [EMBASE: 5334748]
105. Wulff-Woesten A, Ohlendorf D, Henz BM, Haas N. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacology and Physiology 2004;17(2):91-7. [EMBASE: 2004093096]
106. Andres P. Safety assessment of clobetasol proprionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with psoriasis of the scalp. 7th Asian Congress of Dermatology incorporating the 5th Regional Conference of Paediatric Dermatology Kuala Lumpur, Malaysia 28th September - 1st October 2005. 2005:369. [CENTRAL: CN-00602630]
107. NCT01914627 . Parallel group trial to evaluate the efficacy and safety of Loion® compared to 10% salicylic acid in patients with chronic psoriasis capitis. www.clinicaltrials.gov/show/NCT01914627 (accessed 29 April 2015).
108. Berth-Jones J. A multi-centre double blind randomised placebo-controlled parallel group comparison to investigate the efficacy and safety of tacalcitol lotion in patients with psoriasis of the scalp. Dermatology Department, Walsgrave Hospitals NHS Trust, Clifford 1998.
109. Bewley AP. The efficacy and safety of clobetasol proprionate 0.05% shampoo compared to Polytar Liquid in the treatment of scalp psoriasis. Whipps Cross University Hospital NHS Trust 2001.
110. Combemale P. A new treatment in scalp psoriasis: Xamiol formulation and results at 8 weeks [Un nouveau traitement dans le psoriasis du cuir chevelu: Carte d'identite Xamiol et resultats a 8 semaines]. Annales de Dermatologie et de Vénéréologie 2009;136(Suppl 3):542-6. [EMBASE: 2009406815]
111. Graham-Brown R. The efficacy and safety of Clobetasol proprionate 0.5% shampoo compared to Polytar Liquid in the treatment of scalp psoriasis. (Protocol RD.03.SPR.2648). University Hospitals of Leicester, UK 2001.
112. Groves RW. The efficacy and safety of Agent A 0.05% shampoo compared to Agent B liquid in the treatment of scalp psoriasis. Dermatology, Dermatology Department, The Middlesex Hospital, Mortimer 2001.
113. Hutchinson P. Calcitriol solution versus Capasal in scalp psoriasis. University Hospitals of Leicester NHS Trust 1995.
114. Hutchinson P. A multicentre, double blind, randomised, placebo controlled parallel group comparison to investigate the efficacy and safety of tacalcitol lotion (4μg/g) in patients with psoriasis of the scalp. University Hospitals of Leicester NHS Trust 1997.
115. Lebwohl M, Qureshi A, Kianifard F, Steadman J, Guana A, Nyirady J. Secukinumab in the treatment of moderate to severe scalp psoriasis: a study to evaluate efficacy and safety. 73rd Annual Meeting of the American Academy of Dermatology San Francisco, CA United States. Conference Start: 2015/03/20 Conference End: 2015/03/24. Journal of the American Academy of Dermatology 2015;72(5 Suppl 1):AB250.
116. Messenger A. Multi-centre, randomised, active controlled, investigator blinded, parallel comparison study of the efficacy and safety of clobetasol proprionate 0.05% shampoo compared to Polytar Liquid® in the treatment of scalp psoriasis. Dermatology, Directorate of Medicine, Royal Hallamshire, Central Sheffield University Hospitals NHS Trust 2001.
117. Nishiyama H, Zenke Y, Kajiwara T, Kobayashi R, Nakano T, Harada H, et al. The usefulness of camellia oil spray and camellia oil-containing shampoo for treatment of scaling and itching in patients with psoriasis vulgaris. Nishinihon Journal of Dermatology 2010;72(4):405-13. [EMBASE: 2010483819]
118. Pye RJ. MC392 - Efficacy and safety of calcipotriol cream in the treatment of scalp psoriasis. Box No 46, Addenbrooke's NHS Trust, CB2 2QQ 1995.
119. Pye RJ. Calcipotriol solution versus Capasal shampoo in scalp psoriasis. Long term treatment with calcipotriol scalp solution (50μg/ml) in patients with scalp psoriasis. Box No 46, Addenbrooke's NHS Trust, CB2 2QQ 1997.
120. 2010-024033-24 . Double blind, randomized, clinical study to compare the efficacy and safety of betamethasone 0, 05% salicylic acid 2% vs. Diprosalic solution vs. vehicle for the treatment of psoriasis capitis [Doppelblinde, randomisierte klinische Studie zum Vergleich der Wirksamkeit und Verträglichkeit von Betamethason 0, 05% Salicylsäure 2% Lösung vs. Diprosalic Lösung vs. Grundlage bei Patienten mit Psoriasis der Kopfhaut]. www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024033-24 (accessed 20 November 2014).
121. NCT01368887 . Study to test the effectiveness of a new treatment for scalp psoriasis. www.clinicaltrials.gov/show/NCT01368887 (accessed 28 April 2015).
122. NCT01582932 . To evaluate the safety, tolerability and efficacy of calcipotriene foam, 0.005%, versus vehicle foam in pediatric subjects (ages 2-11) with plaque psoriasis. www.clinicaltrials.gov/show/NCT01582932 (accessed 20 November 2014).
123. NCT01707043 . Patient preference of Taclonex ointment to Taclonex scalp suspension in adult subjects with psoriasis vulgaris (PS Taclonex). https://www.clinicaltrials.gov/ct2/show/record/NCT01707043 (accessed 28 September 2015).
124. * NCT02413229. A randomized double blind vehicle controlled dose ranging parallel design multiple site clinical study. https://www.clinicaltrials.gov/ct2/show/record/NCT02413229 (accessed 28 September 2015).
125. * NCT02533973. Long-term treatment of scalp psoriasis with Xamiol® gel in a large adult Chinese population. https://www.clinicaltrials.gov/ct2/show/record/NCT02533973 (accessed 28 September 2015).
126. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. Journal of the American Academy of Dermatology 1986;15(5 Pt 1):1007-22. [MEDLINE: 2878015]
127. Al'Abadie MS, Kent GG, Gawkrodger DJ. The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. British Journal of Dermatology 1994;130(2):199-203. [MEDLINE: 8123572]
128. Arnold WP. Tar. Clinics in Dermatology 1997;15(5):739-44. [MEDLINE: 9313972]
129. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. Journal of Investigative Dermatology 1999;113(5):752-9. [MEDLINE: 10571730]
130. Barker JN. The pathophysiology of psoriasis. Lancet 1991;338(8761):227-30. [MEDLINE: 1676787]
131. Baroni A, Paoletti I, Ruocco E, Agozzino M, Tufano MA, Donnarumma G. Possible role of Malassezia furfur in psoriasis: modulation of TGF-beta1, integrin, and HSP70 expression in human keratinocytes and in the skin of psoriasis-affected patients. Journal of Cutaneous Pathology 2004;31(1):35-42. [MEDLINE: 14675283]
132. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. Journal of Investigative Dermatology 1995;105(1 Suppl):89S-94S. [MEDLINE: 7616005]
133. Bos JD, Spuls PI. Topical treatments in psoriasis: today and tomorrow. Clinics in Dermatology 2008;26(5):432-7. [MEDLINE: 18755361]
134. Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF Jr, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2009;60(6):962-71. [MEDLINE: 19375191]
135. Chang YT, Chen TJ, Liu PC, Chen YC, Chen YJ, Huang YL, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Dermato-Venereologica 2009;89(3):262-6. [MEDLINE: 19479122]
136. Chaput JC, Poynard T, Naveau S, Penso D, Durrmeyer O, Suplisson D. Psoriasis, alcohol, and liver disease. British Medical Journal Clinical Research Ed 1985;291(6487):25. [MEDLINE: 3926048]
137. Christensen PM, Kristiansen IS. Number-needed-to-treat (NNT)--needs treatment with care. Basic & Clinical Pharmacology & Toxicology 2006;99(1):12-6. [MEDLINE: 16867164]
138. Cosmetic Ingredient Review Expert Panel. Final safety assessment of coal tar as used in cosmetics. International Journal of Toxicology 2008;27(Suppl 2):1-24. [PUBMED: 18830861]
139. Day I, Lin AN. Use of pimecrolimus cream in disorders other than atopic dermatitis. Journal of Cutaneous Medicine & Surgery 2008;12(1):17-26. [MEDLINE: 18258153]
140. Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. Journal of Clinical & Aesthetic Dermatology 2011;4(5):32-8. [PUBMED: 21607192]
141. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 3802833]
142. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. Journal of the European Academy of Dermatology & Venereology 2000;14(4):267-71. [MEDLINE: 11204514]
143. Dika E, Bardazzi F, Balestri R, Maibach HI. Environmental factors and psoriasis. Current Problems in Dermatology 2007;35:118-35. [PUBMED: 17641494]
144. Dogra S, Kaur I. Childhood psoriasis. Indian Journal of Dermatology, Venereology & Leprology 2010;76(4):357-65. [MEDLINE: 20657115]
145. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. Journal of Investigative Dermatology 2014;134(6):1542-51. [MEDLINE: 24284419]
146. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medical products indicated for the treatment of psoriasis, 18 November 2004. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf (accessed 20 November 2014).
147. Faergemann J, Borgers M, Degreef H. A new ketoconazole topical gel formulation in seborrhoeic dermatitis: an updated review of the mechanism. Expert Opinion on Pharmacotherapy 2007;8(9):1365-71. [MEDLINE: 17563270]
148. Fluhr J, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clinics in Dermatology 2008;26(4):380-6. [MEDLINE: 18691519]
149. Frankel AJ, Zeichner JA, Del Rosso JQ. Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications. Journal of Clinical & Aesthetic Dermatology 2010;3(10):42-5. [MEDLINE: 20967195]
150. Frez ML, Asawanonda P, Gunasekara C, Koh C, Loo S, Oon HH, et al. Recommendations for a patient-centred approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia Scalp Psoriasis Study Group. Journal of Dermatological Treatment 2014; Vol. 25, issue 1:38-45.
151. Gardinal I, Ammoury A, Paul C. Moderate to severe psoriasis: from topical to biological treatment. Journal of the European Academy of Dermatology & Venereology 2009;23(11):1324-6. [PUBMED: 19470061]
152. Ginsburg IH, Link BG. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. International Journal of Dermatology 1993;32(8):587-91. [MEDLINE: 8407075]
153. Gomez-Moyano E, Crespo-Erchiga V, Martinez-Pilar L, Godoy Diaz D, Martinez-Garcia S, Lova Navarro M, et al. Do Malassezia species play a role in exacerbation of scalp psoriasis? [Les levures Malassezia jouent-elles un rôle dans les poussées du psoriasis du cuir chevelu?]. Journal de Mycologie Médicale 2014;24(2):87-92. [MEDLINE: 24411177]
154. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370(9583):263-71. [MEDLINE: 17658397]
155. Gudjonsson JE. Genetic variation and psoriasis. Giornale Italiano di Dermatologia e Venereologia 2008;143(5):299-305. [MEDLINE: 18833071]
156. Hegemann L, Fruchtmann R, van Rooijen LA, Muller-Peddinghaus R, Mahrle G. The antipsoriatic drug, anthralin, inhibits protein kinase C--implications for its mechanism of action. Archives of Dermatological Research 1992;284(3):179-83. [MEDLINE: 1503504]
157. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58. [MEDLINE: 12111919]
158. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
159. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
160. Horn EJ, Domm S, Katz HI, Lebwohl M, Mrowietz U, Kragballe K, et al. Topical corticosteroids in psoriasis: strategies for improving safety. Journal of the European Academy of Dermatology & Venereology 2010;24(2):119-24. [MEDLINE: 20175860]
161. Jales RD, Nast A, Saconato H, Atallah ÁN, Hirata SH. Topical treatments for scalp psoriasis. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD009687]
162. Khan SA, Williamson DM, Gatecliff M, Tosh J. The treatment of chronic psoriasis a two-centre comparative study. Practitioner 1981;225(1356):932-4. [MEDLINE: 7029508]
163. Kim GW, Jung HJ, Ko HC, Kim MB, Lee WJ, Lee SJ, et al. Dermoscopy can be useful in differentiating scalp psoriasis from seborrhoeic dermatitis. British Journal of Dermatology 2011;164(3):652-6. [MEDLINE: 21155753]
164. Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Archives of Dermatological Research 1990;282(3):164-7. [MEDLINE: 2164359]
165. Kragballe K, Iversen L. Calcipotriol. A new topical antipsoriatic. Dermatologic Clinics 1993;11(1):137-41. [MEDLINE: 8435908]
166. Krueger GG, Bergstresser PR, Lowe NJ, Voorhees JJ, Weinstein GD. Psoriasis. Journal of the American Academy of Dermatology 1984;11(5 Pt 2):937-47. [MEDLINE: 6389615]
167. Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. American Journal of Epidemiology 2012;175(5):402-13. [MEDLINE: 22247049]
168. Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology: International Journal for Clinical and Investigative Dermatology 2007;215(Suppl 1):45-54. [MEDLINE: 18174692]
169. Mahrle G, Bonnekoh B, Wevers A, Hegemann L. Anthralin: how does it act and are there more favourable derivatives?. Acta Dermato-Venereologica. Supplementum. 1994;186:83-4. [MEDLINE: 8073848]
170. Mashaly HM, Masood NA, Mohamed AS. Classification of papulo-squamous skin diseases using image analysis. Skin Research & Technology 2012;18(1):36-44. [MEDLINE: 21338407]
171. Mason AR, Mason JM, Cork MJ, Hancock H, Dooley G. Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. British Journal of Dermatology 2013;169(3):519-27. [MEDLINE: 23796133]
172. Menter A. Goeckerman therapy versus biologics in the treatment of psoriasis. Journal of the American Academy of Dermatology 2010;62(3):516-7. [MEDLINE: 20159322]
173. Niedner R. Glucocorticosteroids in dermatology [Glukokortikosteroide in der Dermatologie]. Dt Ärzteblatt 1996;93(44):A2868-72. [www.aerzteblatt.de/pdf/93/44/a2868_2.pdf]
174. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. British Journal of Dermatology 2003;149(5):960-7. [MEDLINE: 14632799]
175. Ortonne J, Chimenti S, Luger T, Puig L, Reid F, Trueb RM. Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology & Venereology 2009;23(12):1435-44. [MEDLINE: 19614856]
176. Paghdal KV, Schwartz RA. Topical tar: back to the future. Journal of the American Academy of Dermatology 2009;61(2):294-302. [MEDLINE: 19185953]
177. Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). Journal of Allergy & Clinical Immunology 2001;107(2):345-52. [MEDLINE: 11174203]
178. Papp K, Berth-Jones J, Kragballe K, Wozel G, de la Brassinne M. Scalp psoriasis: a review of current topical treatment options. Journal of the European Academy of Dermatology & Venereology 2007;21(9):1151-60. [MEDLINE: 17894698]
179. Patel V, Horn EJ, Lobosco SJ, Fox KM, Stevens SR, Lebwohl M. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. Journal of the American Academy of Dermatology 2008;58(6):964-9. [MEDLINE: 18378352]
180. Prinz JC, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M, et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. European Journal of Immunology 1994;24(3):593-8. [MEDLINE: 8125129]
181. Puig L, Ribera M, Hernanz JM, Belinchon I, Santos-Juanes J, Linares M, et al. Treatment of scalp psoriasis: review of the evidence and Delphi consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology [Tratamiento de la psoriasis del cuero cabelludo. Revisión de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología]. Actas Dermo-Sifiliográficas 2010;101(10):827-46. [MEDLINE: 21159259]
182. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology 1999;41(3 Pt 1):401-7. [MEDLINE: 10459113]
183. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. British Journal of Dermatology 2009;160(5):1040-7. [MEDLINE: 19210498]
184. Roques C, Brousse S, Panizzutti C. In vitro antifungal efficacy of ciclopirox olamine alone and associated with zinc pyrithione compared to ketoconazole against Malassezia globosa and Malassezia restricta reference strains. Mycopathologia 2006;162(6):395-400. [MEDLINE: 17146583]
185. Rosenberg EW, Belew PW. Improvement of psoriasis of the scalp with ketoconazole. Archives of Dermatology 1982;118(6):370-1. [MEDLINE: 6284060]
186. Rzany B, Naldi L, Schafer T, Stern R, Williams H. The diagnosis of psoriasis: diagnostic criteria. British Journal of Dermatology 1998;138(5):917. [MEDLINE: 9666855]
187. Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. British Journal of Dermatology 2013;168(5):954-67. [MEDLINE: 23413913]
188. Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. American Journal of Medicine 2007;120(11):953-9. [MEDLINE: 17976422]
189. Shokeen J, O'Neill JL, Taheri A, Feldman SR. Are topical keratolytic agents needed in the treatment of scalp psoriasis?. Dermatology Online Journal 2014;20(3):-. [MEDLINE: 24656276]
190. Shuster S. Psoriatic alopecia. British Journal of Dermatology 1972;87(1):73-7. [MEDLINE: 5043203]
191. Staubach P, Lunter DJ. Basic or maintenance therapy in dermatology. Appropriate vehicles, possibilities and limitations [Basistherapie in der Dermatologie. Geeignete Grundlagen, Möglichkeiten und Grenzen]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete 2014;65(1):63-72; quiz 73-4. [MEDLINE: 24445946]
192. Stern RS. Psoriasis. Lancet 1997;350(9074):349-53. [MEDLINE: 9251649]
193. Tagami H. Triggering factors. Clinics in Dermatology 1997;15(5):677-85. [MEDLINE: 9313966]
194. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Archives of Dermatology 1992;128(1):39-42. [MEDLINE: 1739285]
195. Tobin AM, Higgins EM, Norris S, Kirby B. Prevalence of psoriasis in patients with alcoholic liver disease. Clinical & Experimental Dermatology 2009;34(6):698-701. [MEDLINE: 19438541]
196. Trowbridge RM, Pittelkow MR. Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris. Journal of Drugs in Dermatology 2014;13(2):111-8. [MEDLINE: 24509958]
197. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics 2012;44(12):1341-8. [PUBMED: 23143594 ]
198. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?. Immunology Today 1995;16(3):145-9. [MEDLINE: 7718088]
199. van de Kerkhof PC, Chang A. Scarring alopecia and psoriasis. British Journal of Dermatology 1992;126(5):524-5. [MEDLINE: 1610698]
200. van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998;197(1):31-6. [MEDLINE: 9693182]
201. van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998;197(4):326-34. [MEDLINE: 9873169]
202. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. American Journal of Clinical Dermatology 2001;2(3):159-65. [MEDLINE: 11705093]
203. van de Kerkhof PC, Kragballe K. Recommendations for the topical treatment of psoriasis. Journal of the European Academy of Dermatology & Venereology 2005;19(4):495-9. [MEDLINE: 15987303]
204. von Stebut E. Significance of topical therapy in clinical situations. Location-dependent principles [Stellenwert der topischen Therapie in klinischen Behandlungssituationen]. Hautarzt 2014;65(3):186-91. [MEDLINE: 24419475]
205. Weischer M, Rocken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion?. Experimental Dermatology 2007;16(5):385-93. [MEDLINE: 17437481]
206. Yamamoto T, Matsuuchi M, Irimajiri J, Otoyama K, Nishioka K. Topical anthralin for psoriasis vulgaris: evaluation of 70 Japanese patients. Journal of Dermatology 2000;27(7):482-5. [MEDLINE: 10935350]
207. Yip SY. The prevalence of psoriasis in the Mongoloid race. Journal of the American Academy of Dermatology 1984;10(6):965-8. [MEDLINE: 6736341]
208. Zeljko-Penavic J, Situm M, Simic D, Vurnek-Zivkovic M. Quality of life in psoriatic patients and the relationship between type I and type II psoriasis. Collegium Antropologicum 2010;34(Suppl 1):195-8. [MEDLINE: 20402318]